

Special Issue

Early-Stage Biomarkers: Metabolomics in Preclinical and Prodromal Disease Detection

Message from the Guest Editor

This Special Issue aims to spotlight the emerging role of metabolomics in identifying biomarkers at the earliest stages of disease progression prior to clinical diagnosis.

For diseases such as cancer, neurodegeneration, cardiovascular disorders, and many others, pathology often advances silently, narrowing the window for timely intervention. This Special Issue seeks to address this critical gap by focusing on metabolomics as a tool to capture early biochemical changes that occur in preclinical and prodromal phases and ultimately enabling earlier detection, improved prognosis, and more effective prevention strategies.

We invite contributions that leverage untargeted and targeted metabolomics approaches to detect and, importantly, validate subtle metabolic alterations that precede overt disease symptoms. Beyond discovery, this Special Issue strongly encourages studies emphasizing robust validation in large cohorts or independent datasets as an essential step for translating biomarkers into clinically actionable tools. We welcome you to submit an abstract in advance to confirm whether the manuscript meets the scope.


Guest Editor

Dr. Sonali Mishra

Department of Endocrinology, Metabolism and Lipid Research,
Washington University School of Medicine, St. Louis, MO 63110, USA

Deadline for manuscript submissions

15 October 2026



Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 8.1
Indexed in PubMed



mdpi.com/si/254781

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 8.1
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo
Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-
Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the second half of 2025).